'Partial agonist' presentation slideshows

Richard Elovich, MPH Columbia University Mailman School of Public Health Medical Sociologist

Oral Substitution Treatment for Opioid Dependence: A Training in Best Practices & Program Design for Nepal. Day 2. March 26-28, 2006 Kathmandu, Nepal UNDP. Richard Elovich, MPH Columbia University Mailman School of Public Health Medical Sociologist

1.37k views • 122 slides

2003-2004 Nervous System Pharmacology Review

2003-2004 Nervous System Pharmacology Review. 2 January 2020 3:21 PM. Adrenocorticotropin (ACTH). Anterior pituitary hormone Anticonvulsant Stimulates synthesis and release of cortisol. Alfentanil. Opioid General anaesthetic Intravenous anaesthetic. Amantadine. Antiviral Antiparkinson

1.04k views • 103 slides

Signal Transduction

Signal Transduction. First lecture. Advanced Biochemistry Course. March 2009. Plasma Membrane Structure and Function. The plasma membrane separates the internal environment of the cell from its surroundings The plasma membrane is a phospholipid bilayer with embedded proteins .

880 views • 71 slides

PRINCIPLES OF PAIN MANAGEMENT & ANALGESIA

768 views • 61 slides

PRINCIPLES OF PAIN MANAGEMENT & ANALGESIA

832 views • 58 slides

Patrick An Introduction to Medicinal Chemistry 3/e Chapter 22 ANTIULCER AGENTS Part 1: Histamine antagonists

1.93k views • 55 slides

Buprenorphine for Pain and for Addiction

Buprenorphine for Pain and for Addiction. David A. Moltz, MD MAPP Clinical Conference April 30, 2010. I. Addiction and Dependence. DSM IV Substance Dependence. A maladaptive pattern of substance use, with 3 or more of: Tolerance Withdrawal

587 views • 48 slides

Buprenorphine for Pain and for Addiction

Buprenorphine for Pain and for Addiction. David A. Moltz, MD MAPP Clinical Conference April 30, 2010. I. Addiction and Dependence. DSM IV Substance Dependence. A maladaptive pattern of substance use, with 3 or more of: Tolerance Withdrawal

606 views • 47 slides

Buprenorphine: An Introduction

Buprenorphine: An Introduction. Walter Ling MD Integrated Substance Abuse Programs UCLA Los Angeles, CA April 21 st 2006 lwalter@ucla.edu www.uclaisap.org. Buprenorphine in the Treatment of Opioid Addiction. Buprenorphine as a medication Development: Historical perspective

633 views • 45 slides

Pharmacodynamics

1.35k views • 42 slides

Pharmacodynamics

479 views • 42 slides

Drugs of Abuse: Psychedelic Agents

Drugs of Abuse: Psychedelic Agents. By: Kimber Bailey. Topics of Discussion. Hallucinogens Defined Types Psychedelic Drugs Classes LSD Psilocybin mushrooms Uses for Psychedelic Drugs Previous practices Past beliefs Psychedelic Psychotherapy Psycholytic Therapy Psychedelic Therapy

545 views • 33 slides

The Science behind Champix: From Idea to Tablet

The Science behind Champix: From Idea to Tablet. Jotham W. Coe and Ivan Efremov , PhDs Department of Neuroscience Pfizer Global Research and Development Groton, CT jwcoe@pfizer.com. C. Everett Koop. Smoking is the Leading Cause of Preventable Death.

579 views • 29 slides

396 views • 28 slides

Pharmacodynamics 2

840 views • 27 slides

Drugs and the Brain Teaser

Drugs and the Brain Teaser. Zak Fallows 2013-07-03 http://datb.mit.edu pharmacology@mit.edu. How the Brain Works. You have about 100 billion brain cells, which are called neurons. Each neuron has about 1,000 connections, called synapses. (This number is extremely variable.)

268 views • 26 slides

Adrenoceptor antagonist drugs

Adrenoceptor antagonist drugs. Pawitra Pulbutr M.Sc. In Pharm (Pharmacology). Objectives.

434 views • 25 slides

Buprenorphine and the NIDA CTN: Research to Practice

Buprenorphine and the NIDA CTN: Research to Practice. Walter Ling & Richard Rawson ISAP/UCLA XIII World Congress of Psychiatry September 14, 2005 Cairo, Egypt rrawson@mednet.ucla.edu www.uclaisap.org. Full agonist. -. Super agonist. -. fentanyl. morphine/heroin. hydromorphone.

331 views • 23 slides

PHC 222 Part(I) Dr. Huda Al Salem

PHC 222 Part(I) Dr. Huda Al Salem. Lecture (7). Factors that affect the efficacy. 2- Concentration-Response Curves: Agonist Antagonist Partial agonist Desensetization. Concentration-Response Curve.

248 views • 17 slides

mechanism of drug action

mechanism of drug action. Objectives : Identify different targets of drug action Differentiate between their patterns of action; agonism versus antagonism Elaborate on drug binding to receptors. Success consists of going from failure to failure without loss of enthusiasm.

164 views • 9 slides